Puma Biotechnology, Inc. — Q1 2013 Form 10-Q
Reporting period: Three months ended March 31, 2013. Puma is a development-stage biopharmaceutical company developing cancer drug candidates; it reported no product revenue.
Financial performance and position
| Metric | Q1 2013 | Q1 2012 / comparison |
|---|---|---|
| Revenue | No product sales | No product sales |
| Operating expenses | $11.806 million | $11.852 million |
| Research and development | $9.532 million | $10.568 million |
| General and administrative | $2.274 million | $1.284 million |
| Net loss | $11.780 million | $11.826 million |
| Basic and diluted loss per share | $0.41 | $0.59 |
| Cash used in operating activities | $18.481 million | $2.785 million |
At March 31, cash and cash equivalents were $91.648 million and marketable securities were $27.070 million, totaling approximately $118.7 million. Working capital was $116.571 million; total liabilities were $22.742 million. The balance sheet reported no debt. Profit margins are not meaningful because the company had no product revenue and incurred operating losses.
Changes and cash-flow drivers
- Net loss was nearly flat year over year, while loss per share improved as weighted-average shares increased from 20.04 million to 28.68 million.
- R&D expense declined by about $1.0 million, principally as costs for legacy trials transferred from Pfizer fell after Puma reached the contractual cost cap. Other clinical-development spending increased as new trials ramped up.
- G&A rose by about $1.0 million, mainly from higher stock-based compensation, professional fees, payroll, and facility costs.
- Operating cash outflow increased substantially. Management cited a roughly $7.9 million payment to the licensor for 2012 services, a $6.7 million increase in licensor receivable, and higher prepaid trial costs. The company expected approximately $9.7 million net of licensor payable to be collected by the end of Q2.
- Investing cash outflow included $27.1 million used to buy marketable securities; this was an investment of funds, not operating expense. There was no financing cash flow in the quarter.
Outlook, risks, and other notable items
- Management estimated that available cash and securities would fund the planned development pace through 2014 and into 2015. It forecast next-12-month R&D spending of $40–45 million and G&A spending of $6–7 million, both excluding stock-based compensation.
- The company expects continued losses and negative operating cash flows and may need additional financing thereafter, or earlier. No committed financing source was in place; future equity financing could dilute shareholders.
- Development programs included oral neratinib (PB272) for advanced breast cancer and non-small cell lung cancer, intravenous neratinib for advanced cancers, and PB357, which Puma planned to evaluate further in 2013. Management did not expect product approval before approximately 2015, assuming no unforeseen safety issues.
- New CRO agreements covered up to approximately $22.6 million for a Phase III breast-cancer trial and $4.1 million for a Phase II lung-cancer trial; an imaging-services agreement was up to $2.5 million. The agreements were cancellable on 30 days’ notice, with payment due for services already rendered.
- Clinical timing and costs depend on trial outcomes, enrollment, manufacturing, and regulatory review. The filing reported a $17.3 million licensor receivable, deemed fully collectible by management, and noted that trial-cost accruals are estimates subject to adjustment.
- Management stated disclosure controls were effective at quarter-end. The company reported no pending legal proceedings and no material change in its previously disclosed risk factors.
Investor verification priorities
- Confirm collection timing and amount of the licensor receivable, including the expected approximately $9.7 million net collection.
- Track actual trial spending against management’s $40–45 million R&D estimate and the CRO commitments.
- Monitor cash burn and whether the stated runway through 2014 and into 2015 remains achievable.
- Review clinical-trial progress, safety and efficacy data, enrollment, and regulatory milestones for the drug candidates.
- Assess future financing needs and potential dilution; the runway estimate depends on development pace and other assumptions.